Incremental cost-utility of sevelamer relative to calcium carbonate for treatment of hyperphosphatemia among pre-dialysis chronic kidney disease patients

Table 4 Incremental cost utility results (lifetime horizon) with discount rate of 1.5 %

Strategy	Cost (S$)	Incremental cost (S$)	QALYs	Incremental QALYs	ICER (S$/QALY)
Calcium carbonate	176,851	0	6.40	0	0
Sevelamer	212,103	35,252	7.05	0.65	53,848

All costs are in Singapore Dollars (S$). ICER incremental cost-effectiveness ratio. Although our study cohort all starts out not requiring dialysis, a large majority of them progress to end-stage renal disease and require dialysis by the end of the model simulation

ISSN: 1471-2369